Frontiers in Cardiovascular Medicine (Nov 2022)

Takotsubo cardiomyopathy Afatinib-related in a non-small cell lung cancer patient: Case report

  • German E. Ramos,
  • German E. Ramos,
  • Christian Caglevic,
  • Christian Caglevic,
  • Juan F. Bulnes,
  • Sergio E. Panay,
  • Sergio E. Panay,
  • Mario I. Zapata,
  • Mario I. Zapata,
  • Andrés J. Daniele,
  • Manuel E. Rodríguez,
  • Manuel E. Rodríguez

DOI
https://doi.org/10.3389/fcvm.2022.1060813
Journal volume & issue
Vol. 9

Abstract

Read online

Endothelial Growth Factor Receptor (EGFR) mutations are frequently found among NSCLC patients. Second-generation Tyrosine Kinase Inhibitor (TKI) Afatinib is frequently used in this population of patients achieving better results than cytotoxic chemotherapy in terms of survival and progression. Afatinib-related cardiotoxicity has been rarely reported. Here we comment on a clinical case of a Takotsubo Cardiomyopathy Afatinib-induced in an NSCLC patient.

Keywords